CLEAR Outcomes Company Update Call: Detailed Results Discussion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Esperion Therapeutics (ESPR) to Buy at Jefferies ahead of ACC
February 24, 2023 11:34 AM ESTJefferies upgraded Esperion Therapeutics (NASDAQ: ESPR) to a Buy rating (From Hold) and doubled the price target on the stock to $6.00 (From $12.00) following incrementally positive management comments heading into the CLEAR CV outcomes data at ACC on March 4th.
Jefferies analysts are confident ESPR should meet or beat the Street's 15% cardiovascular benefit "bar," but even... More
